Actively Recruiting
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Led by Bristol-Myers Squibb · Updated on 2025-09-05
260
Participants Needed
17
Research Sites
207 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
CONDITIONS
Official Title
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with relapsed or refractory multiple myeloma with documented disease progression during or after last therapy
- For Part 1 Dose Finding: refractory to, intolerant to, or not a candidate for available established therapies providing clinical benefit in multiple myeloma
- For Part 2 Dose Expansion: refractory to or relapsed after specified prior therapies including immunomodulatory drugs, proteasome inhibitors, anti-CD38 monoclonal antibodies, and T-cell redirecting therapies unless not a candidate for T-cell redirecting therapy
- Measurable disease
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
- Agree to follow the CC-92480 Pregnancy Prevention Plan
You will not qualify if you...
- Known active or history of central nervous system involvement of multiple myeloma
- Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, or clinically significant light-chain amyloidosis
- Impaired cardiac function or clinically significant cardiac disease
- Previous SARS-CoV-2 infection within 14 days for asymptomatic or mild symptoms or 28 days for severe illness before Cycle 1 Day 1
- For Part 1: prior therapy with CC-92480
- For Part 2: prior therapy with CC-92480, tazemetostat, BMS-986158, or trametinib
- Previous allogeneic stem-cell transplant at any time or autologous stem-cell transplant within 12 weeks before starting study treatment
- Received plasmapheresis, major surgery, radiation therapy (except local therapy for bone lesions), or any systemic anti-myeloma drug therapy within 14 days before starting study treatment
- Used investigational agents within 28 days or 5 half-lives before starting study treatment
- Received COVID-19 vaccine within 14 days before Cycle 1 Day 1
- Other protocol-defined inclusion/exclusion criteria apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 17 locations
1
UAB Comprehensive Cancer Center
Birmingham, Alabama, United States, 35249
Actively Recruiting
2
Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States, 21287
Actively Recruiting
3
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
4
John Theurer Cancer Center at Hackensack UMC
Hackensack, New Jersey, United States, 07601
Actively Recruiting
5
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10021
Actively Recruiting
6
Alberta Health Services AHS - Foothills Medical Centre FMC
Calgary, Alberta, Canada, T2N 5G2
Actively Recruiting
7
University of Alberta - Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Actively Recruiting
8
University Health Network UHN - Princess Margaret Hospital PMH
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
9
Oslo University Hospital
Oslo, Outside US and Canada, Norway, 0450
Actively Recruiting
10
ICO - Hospital Germans Trias i Pujol
Barcelona, Spain, 08026
Actively Recruiting
11
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
Actively Recruiting
12
Hospital Universitario Marques de Valdecilla
Santander, Spain, 39008
Actively Recruiting
13
The Christie NHS Foundation Trust
Manchester, Greater Manchester, United Kingdom, M20 4BX
Actively Recruiting
14
Local Institution - 0001
Leicester, Leicestershire, United Kingdom, LE1 5WW
Withdrawn
15
Local Institution - 0014
Liverpool, Merseyside, United Kingdom, L7 8YA
Withdrawn
16
Churchill Hospital
Oxford, Oxfordshire, United Kingdom, OX3 7LE
Actively Recruiting
17
NIHR UCLH Clinical Research Facility
London, United Kingdom, W1T 7HA
Actively Recruiting
Research Team
B
BMS Study Connect Contact Center www.BMSStudyConnect.com
CONTACT
F
First line of email MUST contain NCT # and Site #.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here